Delivery Order SPE2DB24D9803-SPE2DB25FJSJA
- Not listed
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,385.11 contract is for the delivery of 4565520224 ADVAIR HFA 230-21 MCG INHALER 12GM, with a completion date of August 21, 2024. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a wide range of pharmaceutical products and medical supplies to the Department...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $1,249.43 award is for the delivery of ADVAIR HFA 230-21 MCG INHALER 12GM, a pharmaceutical product, and has a completion date of September 6, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) worth up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,952.07 order is for 4,565,007,305 units of Advair HFA 230-21 MCG Inhaler 12GM, a pharmaceutical product. The delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is valued at $2,638.06 and runs through March 22, 2024. It is not designated as a set-aside contract. The contract is for the delivery of Advair HFA 45-21 MCG inhalers, a pharmaceutical product. This award is likely part of a larger indefinite delivery vehicle (IDV) contract between DMS Pharmaceutical Group and DLA, valued...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,745.46 contract is for the delivery of 4568819007 - ADVAIR HFA 230-21 MCG INHALER 12GM. The order has an ultimate completion date of July 18, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $18,376.12 award is for the supply of the medication ADVAIR HFA 115-21 MCG INHALER 12GM. The award is issued under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract (IDC) with the DLA through the SPE2DB program, which allows the DLA to place delivery orders for a wide range of...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,715.40, is for the delivery of ADVAIR HFA 230-21 MCG INHALER 8GM, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. The contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $1,562.04 for the supply of pharmaceutical products, including Advair HFA 115-21 MCG inhalers. The award was made by the Defense Logistics Agency (DLA), a defense agency, and is part of the SPE2DB indefinite delivery contract (IDC) valued at up to $499,999,999 that runs through December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a...
- This firm fixed-price delivery order for $1,239.58 was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB24 indefinite delivery contract. The order is for the supply of ADVAIR HFA 230-21 MCG INHALER 12GM, a branded pharmaceutical product. This delivery order is part of DMS Pharmaceutical Group's larger $499,999,999 IDC with the DLA, which allows the agency to issue firm fixed-price orders for...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $13,743.12, is for the delivery of ADVAIR HFA 115-21 MCG INHALER 12GM medical supplies. The contract has no set-aside designation and is a firm fixed-price delivery order with an ultimate completion date of September 26, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with...
- SPE2DB24D9803Indefinite Delivery Contract
- SPE2DB24D9803-SPE2DB25FJSJADelivery Order
The Defense Logistics Agency awarded a $4,922.42 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 31, 2025, for the supply of Advair HFA 230-21 microgram inhalers (12 gram units). The contract, which carries an ultimate completion date of August 1, 2025, represents a delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at approximately $500 million through November 2026. No set-aside designation was applied to this award. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as the prime contractor with no identified subcontractors. The company operates as a critical supplier within the federal pharmaceutical supply chain, specializing in the distribution of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. This delivery order for respiratory medication aligns with DMS Pharmaceutical Group's established portfolio of pharmaceutical product deliveries to military health facilities and demonstrates the company's continued role in supporting DLA's medical supply requirements for the defense sector.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 7/31/25 |